A 320-page RICO complaint against three of America’s largest cannabis operators landed in insurance and legal analysis this morning, signalling the litigation risks that federal rescheduling may accelerate. German import data confirms Canada’s commanding share of Europe’s largest medical market, while a federal hemp ban now threatens to undermine a new Medicare reimbursement pilot. A UC San Diego study adds fresh scientific weight to age-gating debates, and Ohio’s failed ballot effort reveals unpaid campaign workers still seeking redress months after the drive collapsed.

RICO Complaint Against Cresco Labs, GTI, and Verano Draws “Big Tobacco” Comparisons

A 320-page class action filed on 4 May in the Northern District of Illinois names Cresco Labs, Green Thumb Industries, and Verano Holdings. Analysis published today by Claims Journal examines the suit, which is brought by more than 40 plaintiffs across 12 states and alleges RICO violations, consumer fraud, and negligent misrepresentation. The complaint accuses all three operators of adopting Big Tobacco’s strategy: sponsoring favourable research while concealing evidence of health harms. RICO carries treble-damages exposure. Medical cannabis rescheduling to Schedule III in April is likely to raise the threshold for safety and labelling compliance, increasing litigation risk across the sector. Track broader operator performance at the Cannabis Stocks Tracker.

Canada Claims 53% of Germany’s Q1 Medical Cannabis Imports

Canadian producers supplied 26,753 kilograms of Germany’s 50,539 kilograms of total medical cannabis flower imports in the first quarter, according to official data reviewed by Hemp Gazette. Portugal ranked second at 10,342 kilograms; Denmark contributed 3,338 kilograms. The aggregate total is up 34% on Q1 2025, though a 15% sequential decline from Q4 2025 suggests seasonal softness. Domestic excise taxes are making the higher-margin European market increasingly attractive for Canadian operators, who met government officials on 4 May to discuss export pathways. EU-GMP certification remains mandatory, but the practice of routing non-certified product through certified processors — known in the trade as “GMP washing” — is drawing regulatory attention. Full market context at the EU Cannabis Regulation Hub.

Federal Hemp Ban Threatens to Undermine New Medicare Reimbursement Pilot

A federal hemp ban taking effect on 12 November 2026 will narrow the definition of legal hemp to a 0.4-milligram total THC cap per container, effectively criminalising most CBD products, reports Hemp Gazette. The ban now conflicts directly with a new Centers for Medicare and Medicaid Services pilot programme that reimburses patients up to $500 annually for hemp-derived products. Courts declined to block the CMS programme following an industry legal challenge, leaving the regulatory contradiction unresolved. The US Hemp Roundtable’s Jonathan Miller cited “political polarisation within Congress” as the obstacle to a legislative fix. Industry groups are seeking either a two-year delay or passage of the Cannabinoid Safety and Regulation Act before the November deadline. For context on the wider rescheduling landscape, see the Cannabis Rescheduling Tracker.

UC San Diego Study Links Frequent Adolescent Cannabis Use to Slower Cognitive Development

Researchers at UC San Diego analysed seven years of data from more than 11,000 children enrolled in the Adolescent Brain Cognitive Development Study, combining self-reported usage with hair-sample testing. The study, reported by Hemp Gazette, found that frequent cannabis users showed reduced improvement in verbal memory, learning, and visual-spatial skills compared with non-users. Attention span and processing speed were also affected. Lead researcher Dr Natasha Wade noted that hair-sample testing captures consistent use over a three-month window, improving on urine-test accuracy. The authors caution this is an observational study and does not establish causation. The findings are expected to strengthen the empirical basis for age-gating and marketing-restriction debates in states still finalising consumer protection frameworks.

Ohio’s Failed Ballot Campaign Leaves Signature Collectors Unpaid

Petitioners who tried to place a ballot measure overturning Ohio Senate Bill 56 — which restricted recreational cannabis and banned intoxicating hemp products — say they were never fully compensated for their work, Marijuana Moment reports. The campaign collected roughly 208,000 of the 248,092 signatures required before halting paid collection on 25 February, three weeks before the March deadline, citing depleted funds. Several collectors describe outstanding payments ranging from $900 to more than $9,000. Campaign consultant Larry Laws told Marijuana Moment: “If it hasn’t happened by now, it’s not going to happen.” The episode illustrates the financial and operational risks of ballot-initiative reform, a strategy that carries substantial costs even in successful campaigns.

Watch this week for Senate appropriators’ response to the House rider that would block further federal cannabis rescheduling, and for developments around the 20 May deadline for mail-in participation notices ahead of the DEA’s June 29 rescheduling hearing. Any movement on the Cannabinoid Safety and Regulation Act ahead of November’s hemp ban deadline will also merit attention.